- Home
- CRDL vs PAYS Comparison
CRDL vs PAYS Comparison
Compare CRDL & PAYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDL
- PAYS
- Stock Information
- Founded
- CRDL 2017
- PAYS 2001
- Country
- CRDL Canada
- PAYS United States
- Employees
- CRDL N/A
- PAYS N/A
- Industry
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- PAYS Business Services
- Sector
- CRDL Health Care
- PAYS Consumer Discretionary
- Exchange
- CRDL Nasdaq
- PAYS Nasdaq
- Market Cap
- CRDL 102.0M
- PAYS 109.6M
- IPO Year
- CRDL N/A
- PAYS 1998
- Fundamental
- Price
- CRDL $1.03
- PAYS $2.22
- Analyst Decision
- CRDL Strong Buy
- PAYS Strong Buy
- Analyst Count
- CRDL 3
- PAYS 3
- Target Price
- CRDL $9.00
- PAYS $5.67
- AVG Volume (30 Days)
- CRDL 226.1K
- PAYS 277.7K
- Earning Date
- CRDL 05-13-2025
- PAYS 05-06-2025
- Dividend Yield
- CRDL N/A
- PAYS N/A
- EPS Growth
- CRDL N/A
- PAYS N/A
- EPS
- CRDL N/A
- PAYS 0.07
- Revenue
- CRDL N/A
- PAYS $58,384,552.00
- Revenue This Year
- CRDL N/A
- PAYS $21.24
- Revenue Next Year
- CRDL N/A
- PAYS $13.64
- P/E Ratio
- CRDL N/A
- PAYS $31.57
- Revenue Growth
- CRDL N/A
- PAYS 23.50
- 52 Week Low
- CRDL $0.77
- PAYS $1.80
- 52 Week High
- CRDL $3.12
- PAYS $5.59
- Technical
- Relative Strength Index (RSI)
- CRDL 50.17
- PAYS 51.35
- Support Level
- CRDL $0.92
- PAYS $2.03
- Resistance Level
- CRDL $1.08
- PAYS $2.18
- Average True Range (ATR)
- CRDL 0.11
- PAYS 0.13
- MACD
- CRDL 0.02
- PAYS 0.04
- Stochastic Oscillator
- CRDL 72.64
- PAYS 81.44
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
About PAYS Paysign Inc.
PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The Company creates customized payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The company's revenues include fees generated from cardholder fees, interchange, card program management fees, transaction claims processing fees, and settlement income.